Carlos Eduardo Brandão Mello
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Centro de Ciências da Saúde
Unidade:
Faculdade de Medicina
Departamento:
Departamento de Clínica Médica/FM
Formação:
-
Universidade Federal de São Paulo
Gastroenterologia | Doutorado | 1996 - 1997
-
Universidade Federal do Rio de Janeiro
Medicina (Gastroenterologia) | Mestrado | 1986 - 1988
-
Universidade Gama Filho
Curso de Especialização Em Medicina do Trabalho | Especialização | 1984 - 1986
-
Santa Casa de Misericórdia do Rio de Janeiro
Gastroenterologia Hepatologia | Especialização | 1980 - 1982
-
Universidade Federal do Estado do Rio de Janeiro
Medicina | Graduação | 1973 - 1979
-
Universidade Federal do Estado do Rio de Janeiro
| Livre Docência | 0 - Agora
-
Universidade Federal do Estado do Rio de Janeiro
| Livre Docência | 0 - Agora
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:
(32.10% artigos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| Renal dysfunction during treatment of chronic hepatitis B with tenofovir disoproxyl fumarate and associated risk factors | 10.1097/meg.0000000000002723 | 2024 |
| Before Direct-Acting Antivirals for Hepatitis C Virus: Evaluation of Core Protein R70Q and L/C91M Substitutions in Chronically Infected Brazilian Patients Unresponsive to IFN and/or RBV | 10.3390/v15010187 | 2023 |
| Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries | 10.1016/j.jhep.2023.02.041 | 2023 |
| Hepatitis C Virus (HCV) Infection and Neurocognitive Impairment in Subjects with Mild Liver Disease | 10.3390/jcm12123910 | 2023 |
| O-36 UTILITY OF DRIED BLOOD SAMPLES FOR HEPATITIS C VIRUS GENOTYPING AMONG HCV/HIV-COINFECTED INDIVIDUALS | 10.1016/j.aohep.2023.101043 | 2023 |
| Cognitive Performance in Asymptomatic Elderly People with Hepatitis C: The Role of Education | 10.3390/jcm12144588 | 2023 |
| Hepatitis C virus (HCV) infection and neurocognitive performance in subjects with mild liver disease | 2023 | |
| Chronic Hepatitis C and aging: search for cognitive changes | 2023 | |
| HCV infection and neurocognitive impairment in subjects with mild liver disease: the role of neuropsychological and cognitive provoked P300 tests | 2023 | |
| Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study | 10.1016/s2468-1253(23)00197-8 | 2023 |
| Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic | 10.20945/2359-4292-2023-0123 | 2023 |
| The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories | 10.1016/j.jhep.2023.10.043 | 2023 |
| Brazilian Society of Hepatology Updated Recommendations for Systemic Treatment of Hepatocellular Carcinoma | 10.1590/S0004-2803.202301000-14 | 2023 |
| Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study | 10.1016/S2468-1253(21)00295-8 | 2022 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study | 10.1016/S2468-1253(21)00472-6 | 2022 |
| CHOOSING WISELY BRAZIL: THE TOP 5 LIST TO AVOID LOW-CARE VALUE INTERVENTIONS IN VIRAL HEPATITIS: POSITION STATEMENT OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH) ENDORSED BY THE LATIN AMERICAN ASSOCIATION FOR THE STUDY OF THE LIVER (ALEH) | 2022 | |
| Cytokine profile during occult hepatitis B virus infection in chronic hepatitis C patients | 10.1186/s12985-021-01487-2 | 2021 |
| Patients with Hepatitis C Infection and Normal Liver Function: A Neuropsychological and Neurophysiological Assessment of Cognitive Functions | 10.1155/2021/8823676 | 2021 |
| Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents | 10.3389/fmed.2021.631600 | 2021 |
| High rate of depression in patients with chronic hepatitis C / Taxa elevada de depressão em pacientes com hepatite C crônica | 10.9789/2175-5361.rpcfo.v13.11384 | 2021 |
| Dried blood spot sampling as an alternative for the improvement of hepatitis B and C diagnosis in key populations | 10.4254/wjh.v13.i4.504 | 2021 |
| The Many Difficulties and Subtleties in the Cognitive Assessment of Chronic Hepatitis C Infection | 10.1155/2020/9675235 | 2020 |
| Cognitive and neurophysiological assessment of patients with minimal hepatic encephalopathy in Brazil | 10.1038/s41598-020-65307-3 | 2020 |
| Hepatic Manifestations of SARS-CoV-2 Infection (COVID-19) | 10.26717/BJSTR.2020.28.004727 | 2020 |
| Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals | 10.1097/MD.0000000000021270 | 2020 |
| The case for simplifying and using absolute targets for viral hepatitis elimination goals | 10.1111/jvh.13412 | 2020 |
| Frequency of Cognitive Impairment in Patients with Chronic Hepatites C at a University Hospital in Rio de Janeiro - Brazil | 2020 | |
| Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1 | 10.1016/j.clinre.2019.02.009 | 2019 |
| Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes | 10.1371/journal.pone.0216327 | 2019 |
| Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil | 10.1016/j.aohep.2019.08.001 | 2019 |
| The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis | 10.3390/v11111000 | 2019 |
| Evaluation of Occult Hepatitis B Infection in Individuals with Chronic Hepatitis C Before Treatment with Oral Direct-Acting Antivirals | 10.5812/hepatmon.92317 | 2019 |
| HEPATITIS C TREATMENT AMONG HCV-HIV CO-INFECTED PATIENTS IN BRAZIL: A MULTICENTER STUDY ON BASELINE RESISTANCE ANALYSES AND SUSTAINED VIROLOGIC RESPONSE RATE | 2019 | |
| Nutritional Assessment, Handgrip Strength and Adductor Pollicis Muscle Thickness In Patients With Chronic Viral Hepatitis | 10.1016/j.yclnex.2019.11.002 | 2019 |
| How are HCV-infected patients being identified in Brazil: a multicenter study | 10.1016/j.bjid.2019.01.006 | 2019 |
| Detection of occult hepatitis B in serum and oral fluid samples | 10.1590/0074-02760170071 | 2018 |
| Impact of vitamin D receptor and binding protein gene polymorphisms in clinical and laboratory data of HCV patients | 10.1097/md.0000000000009881 | 2018 |
| Falha aos DAAs atuais: Como Prevenir e Tratar | 2018 | |
| Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study | 10.1016/S2468-1253(18)30056-6 | 2018 |
| Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C | 10.24171/j.phrp.2018.9.2.03 | 2018 |
| Resistance analysis of hepatitis C virus NS5A gene in Brazilian patients infected with genotype 1 and 3 treated with Dataclatasvir | 2018 | |
| Different core-specific T cell subsets are expanded in chronic hepatitis C with advanced liver disease | 10.1016/j.cyto.2018.06.023 | 2018 |
| Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis | 10.5604/01.3001.0012.2244 | 2018 |
| HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE | 10.1590/s0004-2803.201800000-74 | 2018 |
| Prevalence of sofosbuvir resistance-associated variants in Brazilian and world-wide NS5B sequences of genotype-1 HCV | 10.3851/IMP3131 | 2017 |
| Performance of anti-HCV testing in dried blood spots and saliva according to HIV status | 10.1002/jmv.24777 | 2017 |
| The proportion of different IL-17-producing T cell subsets is associated with liver fibrosis in chronic hepatitis C | 10.1111/imm.12720 | 2017 |
| A interleucina 28-B (IL28-B) como fator preditor de resposta virologica sustentada (RVS) em pacientes coinfectados pelos vírus da hepatite C (HCV) e da imunodeficiência humana (HIV) submetidos a terapia com peginterferon e ribavirina | 2017 | |
| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study | 10.1016/s2468-1253(16)30181-9 | 2017 |
| New Direct action antivirals containing regimes to treat patients with hepatitis C chronic infection:first results from a national real-world registry of the Brazilian Society of Hepatology | 2017 | |
| Evaluation of HBsAg and anti-HBc assays in saliva and dried blood spot samples according HIV status | 2017 | |
| Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study | 10.6061/clinics/2017(06)08 | 2017 |
| Lack of Association between Hepatitis C Virus core Gene Variation 70/91aa and Insulin Resistance | 10.3390/ijms18071444 | 2017 |
| Performance of rapid diagnostic tests for detection of Hepatitis B and C markers in HIV infected patients | 10.1016/j.jviromet.2017.08.001 | 2017 |
| Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus | 10.1590/s1678-9946201759067 | 2017 |
| Taxas de Resposta virologica sustentada (RVS12) em pacientes cirroticos compensados virgens e experimentados tratados com os novos DAAs | 2017 | |
| Avaliação da função hepática de pacientes cirroticos descompensados monoinfectados pelo HCV após tratamento com DAAs | 2017 | |
| Resolução da sobrecarga ferrica em portadores de hepatite C crônica após tratamento com DAA: Série de casos | 2017 | |
| Perfil clinico-epidemiologico dos portadores de hepatite C crônica com fibrose avançada candidatos ao tratamento com os novos antivirais de ação direta | 2017 | |
| Prevalência de eventos adversos em pacientes com HCV tratados com DAAs num Ambulatório de Hepatologia de um Hospital Universitáro | 2017 | |
| Perfil clinico-epidemiologico de pacientes cronicamente infectados com HCV submetidos ao tratamento com DAAs em um serviço de referencia | 2017 | |
| Taxas de Resposta virológica sustentada (RVS12) no tratamento de monoinfectados pelo HCV com fibrose avançada com os novos DAAs | 2017 | |
| Guia de recomendações para tratamento da hepatite C das Sociedades Brasileiras de Hepatologia e Infectologia | 2016 | |
| Coinfecção HCV-HIV Quando e como tratar? | 2016 | |
| Preliminary Results from TOPAZ-III, A Phase 3b Study Evaluating the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in Naive or Experienced Adults in Brazil with HCV Genotype 1 Infection and Advanced Fibrosis/Cirrhosis | 2016 | |
| The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study | 10.1016/j.bjid.2014.08.002 | 2015 |
| IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients | 10.3389/fmicb.2015.00153 | 2015 |
| Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C | 10.1590/0074-02760150104 | 2015 |
| Disease burden of chronic hepatitis C in Brazil | 10.1016/j.bjid.2015.04.004 | 2015 |
| Hepatitis C Virus and Human T-cell Lymphotropic Virus Coinfection: A Epidemiological, Clinical and Laboratory Analysis | 2015 | |
| Sessão de 27 de Agosto de 2015 | 2015 | |
| Sessão de 10 de Novembro de 2015 | 2015 | |
| Interferon-induced depression in patients with hepatitis C: An epidemiologic study | 2014 | |
| Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study | 10.1016/j.bjid.2013.05.007 | 2014 |
| Tratamento da Hepatite crônica pelo vírus C - Novas Perspectivas | 2014 | |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries | 10.1111/jvh.12247 | 2014 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm | 10.1111/jvh.12248 | 2014 |
| Strategies to manage hepatitis C virus (HCV) disease burden | 10.1111/jvh.12249 | 2014 |
| Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha 2b plus ribavirin retreated with peginterferon alpha 2a plus ribavirin and the benefit-risk ratio of retreatment | 2013 | |
| Analysis of Hepatitis C virus (HCV) RNA viral load in platelets of HCV-monoinfected patients receiving antiviral therapy | 2013 | |
| Patients with hepatitis C infection and normal liver function: an evaluation of cognitive function | 2013 | |
| Cognitive Assessment of patients with minimal hepatic encephalopathy in Brazil | 2013 | |
| Low rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil | 2013 | |
| Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomized, double blind, controled phase 2 trial | 2013 | |
| Cirroses Hepáticas Metabólicas | 2013 | |
| Interleukin 28B-related polymorphisms: A pathway for understanding hepatitis C virus infection? | 2013 | |
| Baseline predictors of null-response to peginterferon (pegIFN) alpha 2a (40KD)/ribavirin (RBV) in treatment naive patients with chronic hepatitis C (CHC) infected with genotype : analysis of data from the multinational PROPHESYS cohort | 2012 | |
| Prevalencia e relevãncia das variantes genotípicas dos polimorfismos rs 12979860 (CT) e rs 8099917 (TG) do gene IL28B em pacientes monoinfectados pelo HCV, coinfectados HCV-HIV e individuos não infectados | 2012 | |
| Alterações Endócrinas vistas na infecção crônica pelo virus C - Revisão da Literatura | 2012 | |
| Primary Spleen Lymphoma associated with Hepatitis C virus infection | 2011 | |
| Factor VIII and IX deficiencies related to acquired inhibitors in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribavirin | 2011 | |
| Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis c | 2011 | |
| Venous Thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey | 2010 | |
| Clinical and Epidemiological Aspects of Hepatocellular carcinoma in Brazil | 2010 | |
| Clinical Profile of Hepatitis B virus chronic infection in patients of Brazilian liver reference units | 2010 | |
| O Fígado e Doenças Infecciosas | 2010 | |
| Thrombopoietin and platelet responses in patients undergoing antiviral therapy with pegylated interferon alpha 2b plus ribavirin for chronic hepatitis C virus infection | 2010 | |
| Multivisceral radical en bloc resection with spleen preservation in T4 gastric cancer | 2010 | |
| Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis C patients treated with peginterferon-alpha 2b and ribavirin? | 2009 | |
| Autoimmune thrombocytopenia related to chronic hepatitis C virus infection | 2009 | |
| Retreatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha 2b | 2009 | |
| Peginterferon-alpha 2b and ribavirin: effective in patients with hepatitis C who failed interferon alpha/ribavirin therapy: EPIC 3 | 2009 | |
| Detectionof hepatitis C virus in platelets:evaluating its relationship to antiviral therapy outcome | 2009 | |
| COINFECÇÃO HIV E HCV- Quando e como tratar? | 2009 | |
| Hepatitis B virus Genotypes and Resistance mutations in patients under long term lamivudine therapy:characterization of genotype G in Brazil | 2008 | |
| Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. | 2008 | |
| Re-treatment of prior non-responders to pegylated interferon alfa-2b(12 Kd)/ribavirin (RBV) with pegylated interferon alfa-2a (40Kd) plus RBV: Final efficacy and safety outcomes of the REPEAT study | 2008 | |
| COINFECÇÃO PELOS VIRUS DA HEPATITE B (HBV) E DA IMUNODEFICIÊNCIA HUMANA ( HIV) - ASPECTOS CLINICOS E TERAPÊUTICOS | 2008 | |
| Detection of Hepatitis C virus in platelets: Evaluating its relationship to viral and host factors | 2007 | |
| HOST AND VIRAL BASELINE CHARACTERISTICS IN HEPATITIS C NAIVE AND NON-RESPONDER | 2007 | |
| The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation. | 2007 | |
| The results of a randomized trial looking at 24 weeks versus 48 weeks of treatment with peginterferon alfa 2a (40 KDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1 | 2006 | |
| HCR RNA Negativity After 12 Weeks of Therapy is the Best Predictor of Sustained Viral Response (SVR) in the | 2006 | |
| HCV-RNA in the fourth week as a predictive factor of sustained virological response (SVR) in genotype 1 hepatitis C patients treated with peginterferon alpha 2b and ribavirin | 2006 | |
| Consenso sobre condutas nas hepatites virais B e C - Hepatite C | 2005 | |
| Demographic and anthropometric analysis and genotype distribution of chronic hepatits C patients treated in public and private reference centers in Brazil | 2004 | |
| Hepatitis C virus associated thrombocytopenia: a controlled prospective, virological study | 2004 | |
| Evaluacion prospectiva de la respuesta temprana con peginterferon alfa2a (40Kd) y ribavirina de un estudio clinico aleatorizado que examina los efectos de la duracion del tratamiento en pacientes con hepatitis C infectados con genotipo 1. Reporte preliminar. | 2002 | |
| Hepatite auto-imune | 2001 | |
| Diagnóstico Imunovirologico da Hepatite B | 2001 | |
| Hepatite B - Tratamento com Interferon | 2001 | |
| Hepatite B (HBV) em individuos co-infectados pelo vírus da imunodeficiëncia humana (HIV) | 2001 | |
| Hepatite C , Insuficiencia Renal Cronica e Glomerulonefrite | 2000 | |
| Hepatite C | 2000 | |
| Tratamento da Hepatite Cronica C- Estado Atual | 2000 | |
| Manifestações Reumáticas e autoimunes do vírus da hepatite C | 2000 | |
| Tratamento Farmacológico da Hipertensão Porta | 1999 | |
| Manifestações Extrahepáticas do vírus da hepatite C - Parte 1 e 2 | 1999 | |
| Manifestações Hematologicas da Hepatite C | 1999 | |
| O Pancreas na síndrome da Imunodeficiëncia Adquirida (AIDS) | 1998 | |
| REVISITING THE GOIÂNIA ACCIDENT: MEDICAL AND DOSIMETRIC EXPERIENCES | 1998 | |
| Hepatites Virais de A a G- Uma Revisão | 1996 | |
| Hepatites Virais Agudas e Crônicas | 1995 | |
| A prevalência da Infecção pelo Vírus da Hepatite Delta (VHD) em Hemofílicos HBsAg Positivo | 1994 | |
| Hepatitis C and liver disease in hemophilia. | 1994 | |
| Hepatite C | 1993 | |
| Contribuição ao Estudo da Hepatite Viral C em Hemofílicos | 1991 | |
| Personal Insights on the Goiania Radiation Accident | 1991 | |
| Medical and related aspects of the Goiania Accident. An Overview | 1991 | |
| Clinical and Hematological Aspects of the 137 Cesium - The Goiania Radiation Accident | 1991 | |
| Medical Aspects of 137 Cesium Decorporation- The Goiania Radiological Accident | 1991 | |
| Novel Biodosimetry Methods Applied to Victims of the Goiania Accident | 1991 | |
| Manifestações Cutâneas produzidas pelo Citomegalovirus na sindrome da imunodeficiencia adquirida | 1990 | |
| Hepatite Pós-Transfusional em pacientes de Risco | 1990 | |
| Acometimento Gastrointestinal pelo Citomegalovírus na Síndrome de Imunodeficiência Adquirida (AIDS) | 1989 | |
| Efeito do Propranolol na pressão portal medida atravës de punção esplênica em 27 pacientes com hipertensão porta | 1988 | |
| Hepatite B e Síndrome da Imunodeficiência Adquirida | 1986 | |
| Hemofilia, Hepatite B e Síndrome da Imunodeficiência Adquirida | 1986 | |
| Hepatite Fulminante | 1986 | |
| Epidemia de Toxoplasmose do Sistema Nervoso Central em enfermos com AIDS na cidade do Rio de Janeiro | 1985 | |
| A síndrome de Imunodeficiência Adquirida ( AIDS/SIDA) em pacientes portadores de Hemofilia do Centro de Hematologia Santa Catarina, Rio de Janeiro, Brasil | 1985 | |
| Hepatite B - Prevalência entre os Homens de Penitenciárias Brasilerias | 1984 | |
| Blastomas Renais Benignos Ocultos: I - Tumores Epiteliais e Mesenquimais | 1984 | |
| Blastomas Renais: II - Tumores de Células Intersticiais Renomedulares | 1984 | |
| Citopatologia nos Carcinomas tireoidianos | 1980 | |
| Hemangiossarcoma Hepático | 1980 | |
| Hepatite Pós-Transfusional | 1980 | |
| A controvertida Síndrome de Pickwick | 1979 | |
| Lesões Cardiovasculares no Lupus Eritematoso Disseminado | 1979 | |
| A variante de Prinzmental | 1978 | |
| Anticoncepcionais orais e efeitos colaterais | 1978 | |
| Efeitos colaterais em 32 pacientes com uso de anovulatórios | 1978 |
Eventos:
(0.00% eventos com DOI)